CD8A and myelodysplastic syndrome: For example, patients with various malignancies (that is, breast, lung and renal cancers, MDS and AML) were able to induce WT1-tetramer+CD8+ T-cell responses following vaccination with modified WT1235-243 peptide vaccine formulated with Montanide adjuvant.10 This correlated with a positive clinical response in the form of primary and metastatic tumor regression, reduced WT1/CEA marker expression or reduced leukemic cells, in 12/20 patients.10